[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chikungunya\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chikungunya":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,79,107,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100640150","effects-of-a-rehabilitation-protocol-on-muscle-strength-muscle-fatigue-and-postural-control-in-post-dengue-and-chikungunya-patients-100640150",false,"NCT07600879","Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients","Effects Of A Rehabilitation Protocol On Muscle Strength, Muscle Fatigue And Postural Control In Post-Dengue And Chikungunya Patients: Non-Randomized Clinical Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Individuals of both sexes\n* Residents of the 1st, 4th, or 11th Health Regions of the state of Pará\n* Confirmed diagnosis of Dengue (DENV) and\u002For Chikungunya (CHIKV) infection by serological testing (ELISA or IgG\u002FIgM)\n* Diagnosis confirmed within the last 5 years\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Musculoskeletal instability, including fractures or acute muscle injuries\n* Cognitive deficits impairing the understanding of commands or study procedures\n* History of balance disorders prior to Dengue or Chikungunya infection\n* Obesity\n* Blindness or low vision\n* Hearing impairment","ALL","18 Years",{"count":19,"type":20},54,"ESTIMATED","INTERVENTIONAL",[23],"NA","Introduction: Dengue and Chikungunya arboviral diseases are considered major public health challenges in tropical regions due to high infection rates and the occurrence of musculoskeletal sequelae that impair strength, balance, and functionality. After the acute phase, symptoms such as fatigue, joint pain, muscle weakness, and postural instability are common, reducing quality of life and hindering social and occupational reintegration.Objective: To analyze the effects of a rehabilitation protocol on muscle fatigue, muscle strength, and postural control in post-Dengue and Chikungunya patients.Methods: This is a non-randomized clinical trial conducted at the Integrated Laboratory for Research and Care in Infectious and Sequelae Diseases (LabDIS\u002FUEPA). Individuals of both sexes, aged over 18 years, with a confirmed diagnosis of Dengue and\u002For Chikungunya within the last five years will be included. Data collection will include a clinical interview, surface electromyography of the flexor carpi radialis, tibialis anterior, lateral and medial gastrocnemius muscles, hydraulic and electronic dynamometry, manovacuometry, and baropodometry. The rehabilitation protocol will consist of twenty supervised sessions of aerobic, anaerobic, and respiratory exercises.Expected Results: Improvements in muscle strength, muscle fatigue, and postural control are expected following the intervention.Conclusion: The findings may support physiotherapeutic strategies aimed at improving strength, fatigue, and balance, expanding knowledge on the neuromuscular and respiratory consequences of arboviral diseases, and contributing to the development of evidence-based rehabilitation protocols, with potential positive impacts on healthcare delivery and public health policies.",[26,27],"Dengue","Chikungunya",[29,30,31,32,33,34,35],"dengue","Chikungunya Virus","Muscle Strength","Electromyography","Rehabilitation","Posture","Muscle Fatigue","NOT_YET_RECRUITING","2026-05-20",{"date":39,"type":40},"2026-05-26","ACTUAL",{"date":42,"type":20},"2026-07-01",{"date":44,"type":20},"2027-07-30",{"name":46,"class":47},"Universidade do Estado do Pará","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":21,"phases":60,"briefSummary":62,"conditions":63,"keywords":67,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100623268","early-phase-1-a-phase-i-study-of-pepgnp-chikv-in-healthy-volunteers-100623268","NCT07394426","A Phase I Study of PepGNP-ChikV in Healthy Volunteers","A Phase I, Dose-escalation, Randomized, Single-blind, Placebo-controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of PepGNP-ChikV, a Synthetic Nanoparticle-based T Cell Next-generational Vaccine Against Chikungunya in Healthy Adults","Inclusion Criteria:\n\n1. Healthy individuals aged ≥18 years to ≤60 years of age, inclusive at time of consent, who are not receiving any excluded concomitant medications as detailed in protocol\n2. Informed consent form signed.\n3. Determined to be eligible by the Investigator based on medical history, physical examination, and screening laboratory testing.\n4. Women of childbearing potential\\* are willing to use effective birth control method(s)\\*\\* for a minimum of 14 days prior to dosing through 90 days after last study vaccination.\n5. Male participants with a partner of childbearing potential must agree to use a highly effective method of contraception (e.g. sterilization or male condom) and refrain from sperm donation during the study and for at least 6 months after the last dose of study drug.\n\n   * An individual who has experienced menarche and who is neither permanently surgically sterile (permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy) nor post-menopausal. In line with the guidance provided by the Clinical Trial Facilitation Group (CTFG), a post-menopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However, in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.\n\n     * Females of childbearing potential and males must be willing to use a highly effective (acceptable effective contraceptive measures are only acceptable for IMPs with unlikely human teratogenicity \u002F fetotoxicity in early pregnancy) method of contraception (hormonal or abstinence). Contraceptive methods that can achieve a failure rate of less than 1% per year when used consistently and correctly are considered as highly effective birth control methods. Such methods include:\n\n       • combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:\n\n       o oral\n\n       o intravaginal\n\n       o transdermal\n\n       • progestogen-only hormonal contraception associated with inhibition of ovulation\n\n       o oral\n\n       o injectable\n\n       o implantable\n\n       • intrauterine device\n       * intrauterine hormone-releasing system\n       * bilateral tubal occlusion\n       * vasectomised partner\n       * sexual abstinence, (refraining from heterosexual intercourse during the entire period of risk associated with the study treatments (up to Day 407), if this is the preferred and usual lifestyle of the participant).\n\nExclusion Criteria:\n\n1. Self-reported or documented history of laboratory-confirmed chikungunya or other mosquito-borne (arthropod) disease, such as Zika or dengue within 90 days prior to consent.\n2. Travel in the previous 90 days to areas where exposure to flaviviruses such as Zika, dengue, West Nile Fever are common, as well as areas increasing in cases of chikungunya (refer to the following website: Chikungunya virus disease worldwide overview).\n3. Self-reported or documented receipt of any chikungunya (alphavirus) or flavivirus vaccine (investigational or licensed) within 90 days prior to consent.\n4. Receipt of any licensed vaccine, including COVID-19 vaccine, within the 28 days prior to consent or planned receipt within 90 days following last study vaccination (if unplanned circumstances subsequent to enrolment necessitate the receipt of a licensed vaccine e.g. tetanus and rabies, in unavoidable clinical settings, these should be documented in the source documents by the Investigator and not considered a protocol deviation. However, if the licensed vaccine is not urgently required, it should be delayed until at least 90 days following last study vaccination).\n5. Known systemic hypersensitivity to any of the vaccine components (e.g. gold), or history of a life-threatening reaction to vaccines, or to a vaccine containing any of the same substances.\n6. Acute illness according to Investigator judgment especially if febrile (≥38.0°C).\n7. Screening laboratory testing, including vital signs, ECG, urinalysis and blood laboratory tests, must be within the normal reference ranges; if an isolated abnormality is reported, but is assessed by the Investigator as not clinically relevant the participant may be enrolled and the Investigator's judgement documented in the participant's source data. However, the following laboratory values must be within normal ranges: AST, ALT, bilirubin, all measures of renal function, neutrophil count and platelet count. If the Investigator suspects it to be an erroneous result, it can be repeated; the new result should be used for eligibility determination by the Investigator after documenting any clinical significance to any persistently abnormal result.\n8. A positive SARS-CoV-2 polymerase chain reaction (PCR) or a positive rapid SARS-CoV-2 antigen test at Screening.\n9. Women who are pregnant, or lactating,\n10. Calculated body mass index (BMI) \\> 32.0 kg\u002Fm2.\n11. Participation in another clinical study investigating a vaccine, drug, medical device, or medical procedure within 90 days or five half-lives, whichever is longer, prior to consent or planned participation in such a study during the period of this clinical study.\n12. Receipt of immunoglobulins, blood or blood-derived products within 90 days prior to consent or planned receipt during the period of this chikungunya vaccine study.\n13. Known or suspected congenital or acquired immunodeficiency or autoimmune disease; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy, within 90 days prior to consent; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within 90 days prior to consent).\n14. Self-reported or documented Hepatitis surface antigen (HBsAg) positivity or antibody against human immunodeficiency virus (HIV), Hepatitis B core, or Hepatitis C. If the viral screening sample at the screening visit provides a positive result, the participant will be excluded.\n15. Thrombocytopenia (platelet count \\\u003C150,000\u002FmL) or any coagulation disorder considered clinically significant by the Investigator.\n16. Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or study completion.\n17. Current alcohol abuse or drug addiction (reported or suspected).\n18. Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study or identified as an immediate family member (i.e. parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study. (i.e. in the employment of the clinical study site).",true,"60 Years",{"count":59,"type":20},40,[61],"EARLY_PHASE1","This is a Phase I, randomized, single-blind, placebo-controlled, study of four separate dose cohorts, with a 42-day interval between each vaccine dose, of a novel Chikungunya Peptide Immunotherapy Vaccine in Healthy Adults (18-60 years of age).\n\nAll participants will undergo a screening visit scheduled for a maximum of 28 days before the enrolment in the clinical study and will provide a blood sample for clinical laboratory tests (complete blood count (CBC)\\*, platelet count, alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, serum creatinine and activated partial thromboplastin time (aPTT), human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV)), and a urine sample for tests for Urinary protein, Urinary blood, Urinary glucose and human chorionic gonadotropin β-subunit (βhCG) urine test (only the female participants)) in order to confirm their eligibility for participation in the study.\n\nA total of 40 participants are planned to be enrolled. A randomization system will be used to assign treatment group and participant number at the clinical site.\n\nParticipants will receive 2 injections, 42 days apart. A final visit will take place at Day 407 (i.e. 365 days after last vaccination).\n\nParticipants will be kept under observation for a minimum of one hour after each vaccination to ensure their safety. Reactogenicity data will be collected in all participants after each vaccine injection: solicited injection site reactions will be collected for Days 0-10 and Days 42-52 and solicited systemic reactions will be collected for Days 0-21 and Days 42-63. Unsolicited events will be collected for Days 0-52. Serious adverse events (SAEs) will be reported throughout the study (from inclusion until 12 months after last vaccination). Serious and non-serious medically attended adverse events (MAAEs) and adverse events of special interest (AESIs) will be collected throughout the study (from inclusion until 12 months after last vaccination).",[27,64,65,66,30],"Chikungunya Fever","Chikungunya Virus Infection","Chikungunya Virus Infections",[68],"Infectious disease, chikungunya, T cell priming vaccine, first in human, healthy volunteer","2026-04-23",{"date":71,"type":40},"2026-04-29",{"date":73,"type":20},"2026-08-03",{"date":75,"type":20},"2028-05-01",{"name":77,"class":78},"Gylden Pharma Ltd","INDUSTRY",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":91,"conditions":92,"keywords":93,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":106},"100590926","phase-3-trial-to-evaluate-the-immunogenicity-and-safety-of-the-co-administration-of-live-attenuated-dengue-and-chikungunya-vaccines-compared-to-separate-administration-in-adults-aged-18-to-59-years-100590926","NCT06973772","Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines Compared to Separate Administration in Adults Aged 18 to 59 Years.","Phase 3b, Multicenter, Randomized, Controlled, Double-Blind Clinical Trial to Evaluate the Immunogenicity and Safety of the Co-administration of Live Attenuated Dengue and Chikungunya Vaccines in Adults Aged 18 to 59 Years.","Inclusion Criteria:\n\n1. Male or female adults aged 18 to 59 years at the time of vaccination.\n2. Signed informed consent by the participant or their legal representatives.\n3. Ability to understand, based on the investigator's assessment, and agree to comply with all study procedures, including blood collection.\n\nExclusion Criteria:\n\n1. Participation in another clinical trial within 28 days prior to screening or planned participation in another clinical study during the trial period.\n2. Pre-existing unstable health condition. An unstable health condition is defined as a disease requiring a change in treatment or hospitalization due to disease worsening within 90 days prior to screening.\n3. Vaccination within 14 days prior to screening with any inactivated vaccine or within 28 days prior to screening with any live attenuated vaccine, or planned vaccination with any vaccine up to 28 days after study vaccination.\n4. Known hypersensitivity to any component of the vaccines.\n5. Thrombocytopenia or bleeding disorders that contraindicate intramuscular vaccination or venipuncture for blood collection.\n6. Receipt of immunoglobulins, blood, or blood products within 180 days prior to screening.\n7. Altered immunocompetence (immunosuppression, immunodeficiency, or immunocompromise) primary or secondary due to: Clinical conditions (including but not limited to renal failure, liver failure with cirrhosis, heart failure class III or IV according to the New York Heart Association, HIV infection, and asplenia).\n8. Use of systemic corticosteroids (oral, intravenous, or intramuscular) at a dose equivalent to ≥20 mg\u002Fday of prednisone for more than 14 days or a cumulative dose greater than 280 mg within the last 90 days prior to screening. Topical, inhaled, and intranasal corticosteroids are allowed. Intermittent use (a single dose within the last 30 days prior to screening) of intra-articular corticosteroids is also allowed.\n9. Receipt of antineoplastic agents, immunosuppressants, immunomodulators, or radiotherapy within the last 180 days prior to screening.\n10. Malignancy at the time of screening or a history of malignancy with \\\u003C5 years of disease-free status at screening (except for basal cell carcinoma of the skin and localized prostate cancer under active surveillance).\n11. Abuse of alcohol and illicit drugs within the past 12 months before screening that may compromise study compliance, at the investigator's discretion.\n12. Being part of the study team, having a first-degree relative (parents, children, in-laws, stepchildren, sons-in-law, or daughters-in-law) or living in the same household as a study team member.\n13. Any other clinical condition that, in the investigator's opinion, may interfere with the study results or pose an additional risk to the participant due to study inclusion.\n14. Prior exposure to dengue and chikungunya viruses, i.e., non-reactive IgM and IgG as screened by specific ELISA for both viruses. In case of doubt or indeterminate ELISA results, at least two consecutive samples will be collected. If doubt persists after two test collections, the participant will be excluded.\n15. For female participants of childbearing potential: Pregnancy (confirmed by a positive β-hCG test), breastfeeding, or intention to engage in sexual activity with reproductive potential without using a contraceptive method for 90 days following vaccination.\n16. Previous receipt of any dengue or chikungunya vaccine.","59 Years",{"count":88,"type":20},900,[90],"PHASE3","This randomized, controlled, double blind trial aims at assessing the safety and immunogenicity profiles of the co-administered Live Attenuated Dengue and Chikungunya vaccines comparatively to the isolated administration, in the adult population aged 18 to 59 years without prior exposure to either arbovirus.",[26,27],[29,94,95],"chikungunya","coadministration regimen","2026-03-05",{"date":98,"type":40},"2026-03-06",{"date":100,"type":20},"2026-03-31",{"date":102,"type":20},"2026-10",{"name":104,"class":105},"Butantan Institute","OTHER_GOV",7,{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":56,"sex":16,"minAge":114,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":177,"overallStatus":195,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":48},"100620537","risk-assessment-of-community-spread-of-multiple-endemic-infectious-diseases-in-a-one-health-perspective-100620537","NCT07358910","Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective","RACSMEI","Inclusion Criteria:\n\n* Residency in the village for more than 6 months;\n* Age between 2 and 75 years old at the time of inclusion;\n* For adults: provision of written consent;\n* For children aged 2-17 years: written parental consent form, verbal assent from children aged 13-17 years;\n\nExclusion Criteria:\n\n* Unable to understand or consent;\n* Under guardianship or deprived of liberty;\n* Medical conditions that impede survey participation;\n* Refusal to participate in the study.","2 Years","75 Years",{"count":117,"type":20},10000,"OBSERVATIONAL","RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics. This knowledge gap hinders the design of effective prevention and control strategies.\n\nRACSMEI will improve understanding across multiple pathogens using a multidisciplinary One Health approach. We will answer key questions on burden, ecology, transmission and population immune status to inform targeted and culturally appropriate interventions. The project combines a nationally representative One Health survey, social-science methods, and multiplex, diverse diagnostics to efficiently test for 57 priority pathogens, including zoonotic and vector-borne agents, vaccine-preventable and elimination-targeted diseases, enteric, respiratory, and environmentally transmitted pathogens and selected neglected tropical diseases and parasites relevant to Cambodia.\n\nMathematical modelling will reconstruct and forecast transmission dynamics and assess the potential impact of future public-health strategies. By integrating intersectoral data and innovative methods, RACSMEI will generate actionable evidence for public-health authorities, support precision One Health interventions, and help reduce disease burden in affected communities. The project also aims to ensure the transferability of methods and insights to other countries facing similar challenges.",[26,27,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,153,154,155,156,157,158,159,160,161,162,163,164,165,166,167,168,169,170,171,172,173,174,175,176],"Zika Virus Infection","Japanese Encephalitis","West Nile Virus","Tick-borne Encephalitis (TBE)","Severe Fever With Thrombocytopenia Syndrome","Nipah Virus Infection","Hantavirus Infections","Hepatitis E","Brucellosis","Q Fever","Leptospirosis","Melioidosis","Influenza A and B","Malaria","Yellow Fever","Mayaro Fever","Usutu Virus Infection","Oropouche Fever","Rift Valley Fever","Arenavirus Infections","Measles","Mumps","Rubella","Human Papilloma Virus (HPV)","Rotavirus Disease","Pertussis","Diphteria","Tetanus","Varicella","Hepatitis A","Norovirus Infections","Enterovirus","Adenovirus","Rhinovirus","Parvovirus","Respiratory Syncytial Virus (RSV)","Cytomegalovirus","Epstein Barr Virus","Salmonella Typhi","Vibrio Cholerae","Legionella Pneumophila Pneumonia","Mycoplasma","Chlamydia","Lymphatic Filariasis","Toxoplasma Gondii","Giardiasis","Entamoeba Histolytica","Leishmaniasis","Strongyloides Stercoralis Infection","Ascaris Lumbricoides","Trichuris Trichiura","Clonorchis Sinensis","Opisthorchis Viverrini","Schistosomiasis","Streptococcus Pneumoniae","Meningitis",[178,179,180,181,182,183,184,185,186,187,188,189,190,191,192,193,194],"Infectious disease","One Health","Population-based survey","Nationally representative survey","Seroepidemiology","Multiplex serology","Seroprevalence","Vector-borne diseases","Zoonoses","Vaccine-preventable diseases","Neglected tropical diseases","Transmission dynamics","Force of infection","Mathematical modelling","Spatial epidemiology","Precision public health","Cambodia","RECRUITING","2026-01-14",{"date":198,"type":40},"2026-01-22",{"date":200,"type":40},"2025-12-18",{"date":202,"type":20},"2027-09-30",{"name":204,"class":47},"Institut Pasteur du Cambodge",{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":209,"acronym":210,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":212,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":214,"conditions":215,"keywords":218,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":4},"100601619","prospective-clinical-registry-for-evaluation-of-exanthematous-infections-and-coinfections-100601619","NCT07112846","Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections","CRIUS","Inclusion Criteria:\n\nIndividuals from newborns (zero years old) to 18 years of age, of both sexes.\n\nSuspected individuals with the following criteria:\n\nMeasles: Presenting fever and rash associated with cough and\u002For runny nose and\u002For conjunctivitis, regardless of age or vaccination status;\n\nRubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;\n\nDengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and\u002For lymph node enlargement;\n\nIndividuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases.\"\n\nExclusion Criteria:\n\n\\-",{"count":213,"type":20},830,"Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.",[216,217,27,141,143],"Exanthema","Dengue Fever",[219,220,27,221,222,223],"exanthema","dengue fever","measles","rubella","epidemiology","2025-08-01",{"date":226,"type":40},"2025-08-08",{"date":228,"type":20},"2025-09-01",{"date":230,"type":20},"2026-06-30",{"name":232,"class":47},"Hospital Israelita Albert Einstein"]